ストックスクリーナーアプリを入手
3.58
3.50%
-0.13
アフターアワーズ：
3.58
前日終値:
$3.71
開ける：
$3.74
24時間の取引高:
18.84M
Relative Volume:
0.82
時価総額：
$1.86B
収益：
$64.60M
当期純損益:
$-377.75M
株価収益率:
-2.3097
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
+0.56%
1か月 パフォーマンス:
-25.57%
6か月 パフォーマンス:
-33.83%
1年 パフォーマンス:
-57.07%
1日の値動き範囲:
$3.49
$3.75
1週間の範囲:
$3.49
$4.0893
52週間の値動き範囲:
$3.49
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.58 | 1.93B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 12-Month LowTime to Sell? - MarketBeat
Recursion reports grant of inducement awards as permitted by the Nasdaq Listing Rules - marketscreener.com
Recursion Pharmaceuticals stock hits 52-week low at $3.53 - Investing.com
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - marketscreener.com
Baillie Gifford's Strategic Adjustment in Recursion Pharmaceuticals Inc - GuruFocus
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Trade Below Fair Value Estimate - Yahoo Finance
This $4 Stock Could Be Your Ticket to Millionaire Status - The Globe and Mail
Recursion Pharmaceuticals stock hits 52-week low at $3.78 By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares - MarketBeat
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k By Investing.com - Investing.com Nigeria
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k - Investing.com
Recursion Pharmaceuticals Stock Jumps on Promising TUPELO Trial Results - StocksToTrade
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors - TipRanks
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $8.66 Million Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Biotech Stocks To Add to Your WatchlistFebruary 5th - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 52-Week LowWhat's Next? - MarketBeat
Boardroom Moves Shake Recursion Pharma Stock - timothysykes.com
Recursion Pharmaceuticals stock hits 52-week low at $3.78 - Investing.com
Recursion Pharmaceuticals (RXRX) Stock Analysis: Biotech Innovator with 67% Potential Upside - DirectorsTalk Interviews
OpenAI considers backing AI-led drug discovery firms: report - Seeking Alpha
Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX) - MSN
Is Recursion Pharmaceuticals Inc. (RXRX) the best overlooked penny stock to invest in? - MSN
Short Squeeze: Is Recursion Pharmaceuticals Inc forming a bullish divergenceJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
Aug Setups: Is Recursion Pharmaceuticals Inc forming a bullish divergence2025 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors - Yahoo Finance
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift - Newswire Canada
Forget 2025: These 2 Growth Stocks Could Soar in 2026 - AOL.com
Recursion Pharmaceuticals Faces Challenges and Opportunities - Intellectia AI
Can This Beaten-Down AI Stock Bounce Back in 2026? - The Globe and Mail
Can This Beaten-Down AI Stock Bounce Back in 2026? - The Motley Fool
Risk Analysis: Will Canadian Solar Inc benefit from green energy policiesPortfolio Value Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Exploring a 52.51% Potential Upside in Biotech - DirectorsTalk Interviews
Aug Final Week: Will Recursion Pharmaceuticals Inc benefit from green energy policies2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Will Nvidia-Backed BioHive-2 and Big Pharma Alliances Redefine Recursion Pharmaceuticals' (RXRX) Narrative - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Valuation Check After Analyst Optimism Insider Buying And Nvidia AI Partnership - simplywall.st
Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? - Finviz
Is Recursion (RXRX) Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage? - Sahm
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Recursion Pharma director Gibson sells $178,800 in stock By Investing.com - Investing.com Canada
Recursion Pharma director Gibson sells $178,800 in stock - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 10.8%Here's Why - MarketBeat
Biotech Stocks To Keep An Eye OnJanuary 22nd - MarketBeat
Recursion Shines at J.P. Morgan Healthcare Conference - StocksToTrade
Recursion Pharmaceuticals Boosts Visibility With J.P. Morgan Conference - timothysykes.com
How Do Investors Really Feel About Recursion Pharmaceuticals Inc? - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory - Insider Monkey
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
Recursion Pharmaceuticals Inc (RXRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Feb 03 '26 |
Sale |
4.20 |
220,000 |
924,000 |
6,429,863 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):